NCT01613586已完成2 期
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 287
- 试验地点
- 60
- 主要终点
- Change from baseline in Mean Daily Pain (MDP) at 12 weeks
研究概览
简要总结
In this study several dose levels of ASP3652, given orally for 12 weeks, will be compared with placebo in the treatment of female patients with Bladder Pain Syndrome / Interstitial Cystitis.
详细描述
This study consists of a screening phase, an initial 3 weeks Run-in period,
a 12 weeks Treatment period and a 2 weeks Follow-up (FU) period.
This study will investigate the efficacy and safety of a 12 week treatment with ASP3652 in female patients with Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC). Different dose levels of ASP3652 will be compared with placebo. ASP3652 is administered as oral tablets. The objectives of the study are to investigate efficacy of ASP3652 in patients with BPS/IC, to assess the optimal dose of ASP3652, to investigate safety and tolerability and to investigate pharmacokinetics and pharmacodynamics of ASP3652 in patients with BPS/IC in an out-patient setting.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Has previously been diagnosed with BPS/IC; i.e., pelvic pain, pressure or discomfort perceived to be related to the urinary bladder accompanied by at least one other urinary symptom such as persistent urge to void or frequency, for at least 3 months prior to screening in absence of urinary infection or other obvious pathology or identifiable causes
- •Has at enrolment a score of 4 or greater on the 11-point (0-10) NRS for average pain over the previous week, which is item 4 of the F-GUPI
- •Has a mean pain score of 4.0 or greater on the 11-point (0-10) NRS for daily assessed pain (item 4 of F-GUPI-24H) over the last 7 days prior to randomization
- •Is willing to comply with study requirements such as completing the questionnaires and diaries and attend all study visits and practicing birth control
排除标准
- •Undergone a cystoscopy with hydrodistension or undergone Botox injections in the bladder within 6 months prior to screening
- •Use of pentosan polysulphate sodium within 4 weeks prior to screening
- •Any intravesicular pharmacological treatment or other interventions for BPS/IC or bladder, urethral, ureteral, pelvic or peri-pelvic invasive procedure within 3 months prior to screening
- •Cystitis or documented symptomatic bacterial cystitis in the last 3 months prior to screening
- •Lower urinary tract malignancy, such as positive (micro) hematuria in urine sediment
- •Neurologic disease or defect affecting bladder function or symptomatic urethral diverticulum or any post-partum or surgery related genital tract conditions, symptomatic bladder or ureteral calculi or Post Void Residual volume greater than 150 mL
- •Clinically significant abnormalities observed during cystoscopy or on transabdominal ultrasound
- •Currently active or treated sexual transmittable diseases
- •Substance abuse or any use of delta-9-tertrahydrocannabinol (THC) as assessed by a positive urine test for THC at screening
- •Any clinically relevant concomitant disease (past or present) which would, in the opinion of the investigator, put the subject at risk or mask measures of efficacy
- •Symptoms of depression, defined as a Center for Epidemiological Studies Depression Scale score of 27 or more
- •Use of steroids, immunomodulators, cytochrome P4502C8 inhibitors, cannabis / THC based medication, opioid analgesics or antiviral / antibacterial / antifungal agents during the last 4 weeks before the screening
- •Initiation, discontinuation, or variation in the dose of antidepressants, anticonvulsants, antimuscarinics, benzodiazepines, skeletal muscle relaxants, non-steroid anti-inflammatory drugs, non opioid analgesics, homeopathic medication and herbal therapies during the last 4 weeks before the screening. Subjects should continue these medications at that same stable dose throughout the study
- •Clinically relevant abnormal urine or blood safety laboratory values or active hepatic and/or biliary disease (AST or ALT should not be >2 times the upper limit of normal, total bilirubin should not be >1.5 times the upper limit of normal)
- •Participated in any clinical study or has been treated with any investigational drug or device within 84 days or the period stipulated by local regulations, whichever is longer, prior to the screening
研究组 & 干预措施
Placebo
Placebo Comparator
Matching placebo twice daily for 12 weeks
干预措施: Placebo (Drug)
Low dose ASP3652 twice daily
Experimental
50 mg twice daily for 12 weeks
干预措施: ASP3652 (Drug)
Medium dose ASP3652 twice daily
Experimental
150 mg twice daily for 12 weeks
干预措施: ASP3652 (Drug)
High dose ASP3652 twice daily
Experimental
300 mg twice daily for 12 weeks
干预措施: ASP3652 (Drug)
结局指标
主要结局
Change from baseline in Mean Daily Pain (MDP) at 12 weeks
时间窗: Baseline and 12 weeks
Pain is assessed on an 11 point (0-10) Numerical Rating Scale (NRS), which is item 4 of the Female GenitoUrinary Pain Index (24 hours recall) (F-GUPI-24h)
次要结局
- Assessment of pharmacokinetics at week 4, 8 and 12(4, 8 and 12 weeks treatment)
- Assessment of pharmacodynamics at week 4, 8 and 12(4, 8 and 12 weeks treatment)
- Safety as assessed by recording Adverse Events, Laboratory tests, electrocardiograms (ECGs) and vital signs(Baseline and 12 weeks treatment)
- Change from baseline in questionnaires (Center for Epidemiologic Studies Depression Scale and Profile of Mood States questionnaire) at 12 weeks treatment(Baseline and 12 weeks treatment)
- Change from baseline in Mean Daily Pain (MDP) at 4, 8 weeks treatment and at 2 weeks follow-up post treatment(Baseline, 4 and 8 weeks treatment and 2 weeks follow-up post treatment)
- Change from baseline in Female GenitoUrinary Pain Index (one week recall) (F-GUPI) Total score at 4, 8, 12 weeks treatment and at 2 weeks follow-up post treatment(Baseline, 4, 8, 12 weeks treatment and 2 weeks follow-up post treatment)
- Change from baseline in F-GUPI Pain subscale score, Urinary subscale score, and Quality of Life Impact score at 4, 8, 12 weeks treatment and at 2 weeks follow-up post treatment(Baseline, 4, 8, 12 weeks treatment and at 2 weeks follow-up post treatment)
- Daily pain, assessed with item 4 of the F-GUPI-24h during Run-in, Treatment period and Follow-up post treatment(Every day during the Run-in, Treatment and Follow-up post treatment periods)
- Change from baseline in questionnaires at 12 weeks treatment(Baseline and 12 weeks treatment)
- Global Response Assessment (GRA) at 0, 4, 8 and 12 weeks treatment and at 2 weeks follow-up post treatment(Baseline, 4, 8, 12 weeks treatment and 2 weeks follow-up post treatment)
- Change from baseline in Voiding parameters (urinary frequency, urinary urgency, nocturia and total urgency score ) at 4, 8, 12 weeks treatment and at 2 weeks Follow-up post treatment(Baseline, 4, 8, 12 weeks treatment and 2 weeks follow-up post treatment)
- Proportion of responders: at least 7-point decrease in F-GUPI Total score at 0, 4, 8 and 12 weeks treatment compared to baseline(Baseline, 4, 8 and 12 weeks treatment)
- Safety as assessed by SteatoTest, adiponectin and PVR(Baseline and 12 weeks)
- Physician Withdrawal Checklist at 12 weeks treatment and at 2 weeks follow-up post treatment(12 weeks treatment and 2 weeks follow-up post treatment)
研究者
研究点 (60)
Loading locations...
相似试验
已完成
2 期
A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)Chronic Abacterial ProstatitisChronic Pelvic Pain SyndromeNCT01391338Astellas Pharma Inc239
已完成
1 期
A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652Healthy SubjectsPharmacokinetics of ASP3652Pharmacodynamics of ASP3652NCT02243657Astellas Pharma Europe B.V.101
已完成
2 期
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe PsoriasisPsoriasisNCT01096862Astellas Pharma Inc124
终止
2 期
Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral NeuropathyPainful Diabetic Peripheral Neuropathy (PDPN)NCT02372578Astellas Pharma Global Development, Inc.115
已完成
2 期
A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the KneeOsteoarthritis of the KneeChronic Lower Back PainNCT02611466Astellas Pharma Europe B.V.215